FDA Peptide Research
Regulations 2026
The September 2024 FDA action placed BPC-157, TB-500, CJC-1295, Ipamorelin, and GHK-Cu on the Category 2 503A prohibited list. Here is what that means — and what it does not mean — for peptide research.
Research purposes only. All products discussed are intended for laboratory research use only. Nothing in this article constitutes legal or medical advice. Regulatory information is current as of March 2026 and subject to change. Verify current status through FDA.gov and consult qualified legal counsel for jurisdiction-specific guidance.
All content is for educational and research purposes only. Peptides discussed are research compounds not approved by the FDA for human use. Nothing on this page constitutes medical advice.
In September 2024, the FDA finalized its decision to place several widely researched peptides on the Category 2 503A bulk drug substances list. This action was the culmination of a multi-year review process and has had significant implications for how these compounds are accessed in clinical contexts.
The action is widely misunderstood. Headlines declared peptides “banned.” The reality is more nuanced: the FDA restricted a specific commercial channel (licensed compounding pharmacies producing patient-specific preparations) while leaving the research use framework largely unchanged.
This article explains the 503A framework, what Category 2 means, which compounds were affected, and what researchers need to know about accessing these compounds legally for laboratory work.
Regulatory Status at a Glance
As of March 2026 — verify on FDA.gov for current status
BPC-157
Category 2 503A — September 2024
503A compounding prohibited; research channel unchanged
TB-500 (Thymosin Beta-4)
Category 2 503A — September 2024
503A compounding prohibited; research channel unchanged
CJC-1295
Category 2 503A — September 2024
503A compounding prohibited; research channel unchanged
Ipamorelin
Category 2 503A — September 2024
503A compounding prohibited; research channel unchanged
GHK-Cu
Category 2 503A — September 2024
503A compounding prohibited; research channel unchanged
Melanotan II
Category 2 503A + no approved use
503A compounding prohibited; also no legitimate research indication
PT-141 (Bremelanotide)
Category 2 503A; FDA-approved form (Vyleesi) exists
503A compounding prohibited; FDA-approved version requires Rx
Semaglutide (Wegovy/Ozempic)
FDA-approved drug
Prescription required for clinical use; research grade sold separately
Tirzepatide (Zepbound/Mounjaro)
FDA-approved drug
Prescription required for clinical use; research grade sold separately
Retatrutide
Investigational — Phase 3 trials
Not approved; available as research peptide only
Epithalon
No FDA action; unapproved
Available as research peptide; no compounding history
IGF-1 LR3
No FDA action; unapproved
Available as research peptide; no compounding history
Understanding 503A: What It Is and Who It Covers
The regulatory channel the September 2024 action actually targeted
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies — licensed pharmacies that prepare customized medications for individual patients with valid prescriptions. These are the pharmacies that might prepare a compounded hormone formulation at a specific dose that is not available commercially, or a semaglutide preparation for a patient with a documented allergy to an excipient in the branded product.
For a compound to be legally compounded by a 503A pharmacy, it must appear on either the Category 1 list (substances nominated and approved for compounding based on clinical need) or not be subject to specific restrictions. The Category 2 list is where the FDA places substances that do not meet the criteria for 503A compounding — meaning they cannot be used in 503A pharmacy preparations for patients.
503A Category 1 (Allowed)
- • Substance nominated and approved through FDA review
- • Clinical need documented
- • Safety data reviewed
- • Can be prepared for individual patient prescriptions
503A Category 2 (Prohibited)
- • Does not meet 503A criteria
- • Cannot be compounded for patient prescriptions
- • Does NOT mean illegal to possess for research
- • Does NOT apply to 503B outsourcing facilities
503B Is a Different Framework
503B “outsourcing facilities” are large-scale, FDA-registered manufacturers that produce compounded drugs for healthcare providers (hospitals, clinics) without patient-specific prescriptions. They operate under tighter manufacturing standards (CGMPs) and different FDA oversight than 503A pharmacies. The September 2024 Category 2 action applies to 503A facilities. Whether 503B facilities can continue compounding Category 2 substances is a separate regulatory question governed by 503B-specific rules.
What the Category 2 Action Does — and Does Not — Mean
What It DOES Mean
- • Licensed 503A compounding pharmacies cannot prepare BPC-157, TB-500, CJC-1295, Ipamorelin, or GHK-Cu for patient prescriptions
- • Patients who previously obtained these compounds via compounding pharmacy prescriptions can no longer do so through that channel
- • Pharmacists and prescribers who continue preparing or prescribing these formulations via 503A facilities face regulatory risk
- • The primary legal channel for clinical use (the prescription-compounding model) is closed for these specific compounds
What It Does NOT Mean
- • It does not make possession of these research peptides illegal for laboratory research purposes
- • It does not prohibit purchase of research-grade peptides from suppliers for in vitro or preclinical studies
- • It does not apply to 503B outsourcing facilities (different regulatory framework)
- • It does not affect academic research institutions using these compounds in approved research protocols
- • It does not affect the research peptide supplier market, which operates outside the 503A compounding framework
- • It does not reflect a determination that these compounds are unsafe or without research value — it reflects the 503A criteria evaluation process
Per-Compound Regulatory Analysis
BPC-157
FDA Status: Category 2 503A (September 2024). Not FDA-approved for any indication. Investigational new drug (IND) application has been filed for human trials by some researchers.
Research Evidence Base: The most extensively studied compound on this list — over 36 published studies primarily from Dr. Predrag Sikiric's group at the University of Zagreb. All published data is preclinical (rodent models). Only three human pilot studies exist: knee pain (intraarticular), interstitial cystitis, and IV pharmacokinetics safety.
What the Action Reflects: The FDA's Category 2 determination is based on the 503A criteria: whether the substance has been used under an approved IND, whether it is a component of an FDA-approved drug, and whether there are safety concerns. BPC-157 meets none of the criteria for Category 1 approval — not because it is proven unsafe, but because the human clinical trial program has not advanced to the point where the FDA can evaluate it under the 503A criteria.
Research Availability: Available as a research-grade peptide from specialized suppliers. For full mechanism and data, see our complete guide to peptide stacking.
TB-500 (Thymosin Beta-4)
FDA Status: Category 2 503A (September 2024). Not FDA-approved. Note: Thymosin Beta-4 itself has been investigated in several FDA-cleared clinical trials for cardiac and wound healing applications (RegeneRx Biopharmaceuticals), though none reached approval.
Research Evidence Base: Strong mechanistic data on actin sequestration and ILK-mediated cell migration (Bock-Marquette et al., Nature 2004). Preclinical wound healing data from multiple independent groups. Clinical trials for cardiac repair and corneal healing were conducted but did not result in approval.
What the Action Reflects: Similar to BPC-157 — lacks the clinical trial data and approval pathway required for 503A Category 1 eligibility.
Research Availability: Available as a research-grade peptide. Commonly studied in combination with BPC-157 as the “Wolverine Stack.”
CJC-1295 and Ipamorelin
FDA Status: Both are Category 2 503A (September 2024). Not FDA-approved. Note: Sermorelin (a related GHRH analog) was previously FDA-approved as Geref but has been discontinued from the commercial market.
Research Evidence Base: CJC-1295 has human Phase 1/2 clinical data (Teichman et al., JCEM 2006) demonstrating 2-10x GH elevation. Ipamorelin has published human pharmacokinetic data with documented GH selectivity (no ACTH/cortisol elevation). Both have stronger human data than BPC-157 or TB-500, but neither has progressed to Phase 3 trials.
What the Action Reflects: Despite existing human Phase 1/2 data, neither compound has a developer pursuing FDA approval with a full Phase 3 program. Without an active IND and development pathway, they cannot qualify for 503A Category 1.
Research Availability: Available as research-grade peptides individually and as the CJC-1295/Ipamorelin combination. See our top peptides for muscle growth guide for mechanism details.
GHK-Cu
FDA Status: Category 2 503A (September 2024). Topical GHK-Cu has been used in cosmetic formulations that are regulated as cosmetics (not drugs) and are not subject to the 503A framework. The 503A action applies to compounded injectable or therapeutic preparations.
Important Distinction: GHK-Cu in cosmetic serums and creams (at typical concentrations of 0.1-3%) remains available as cosmetic products, which are governed by cosmetic regulations, not drug compounding rules. Only pharmaceutical-grade injectable or therapeutic preparations through 503A pharmacies are affected.
Research Evidence Base: Broad Institute Connectivity Map data: significant gene expression effects on 4,000+ genes. Clinical studies showing wrinkle reduction. No large-scale RCT for systemic anti-aging claims. See our complete GHK-Cu guide for evidence grades.
The Research Use Framework: What Remains Available
The research-use-only (RUO) framework for laboratory chemicals and biological research reagents operates largely outside the 503A compounding restrictions. Peptides sold as research chemicals for in vitro or preclinical research are not subject to the FDA drug compounding regulations that govern 503A pharmacies.
This means that researchers can continue to purchase BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, and similar compounds as research-grade peptides from specialized suppliers — as long as those products are labeled for research use only and are not represented as pharmaceutical preparations for human therapeutic use.
Research peptide suppliers like Clav Tides operate in this framework, providing research-grade peptides with certificates of analysis (COA), HPLC purity data, and mass spectrometry confirmation for laboratory and preclinical research applications.
What to Look for in a Research Peptide Supplier
- Certificate of Analysis (COA) with HPLC purity percentage (>98% for research grade)
- Mass spectrometry confirmation of molecular weight
- Research-use-only labeling
- Proper lyophilization and cold-chain shipping
- Avoid suppliers making therapeutic or dosing claims
- Avoid suppliers without third-party COA documentation
What to Watch in 2026 and Beyond
The regulatory trajectory for research peptides in 2026 follows two parallel tracks:
Track 1 — GLP-1 class advancement: Retatrutide is in Phase 3 trials with TRIUMPH readouts expected throughout 2026. If results continue to show -28.7% weight loss efficacy, a regulatory submission could come late 2026, with potential FDA approval in 2027-2028. This would make retatrutide the third GLP-1 class drug to receive approval after semaglutide and tirzepatide. See our retatrutide clinical analysis for the full data picture.
Track 2 — BPC-157 and TB-500 clinical trials: The Category 2 action creates pressure for any developer interested in these compounds to pursue formal IND status and Phase 1/2 clinical trials — the only pathway to potentially restoring 503A eligibility. No major pharmaceutical sponsor has publicly announced a formal IND program for BPC-157 or TB-500 as of March 2026, though smaller biotechnology firms have filed safety/pharmacokinetics pilots.
Track 3 — Further FDA 503A list updates: The FDA's review process for 503A substances is ongoing. Additional compounds may be added to Category 2, or some may be moved to Category 1 if developers successfully complete the nomination and evidence review process. Researchers should monitor FDA.gov's bulk drug substances list for updates.
Frequently Asked Questions
What was the September 2024 FDA action on peptides?
In September 2024, the FDA finalized placement of BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, Melanotan II, and PT-141 on the Category 2 503A bulk drug substances list. This prohibits licensed 503A compounding pharmacies from preparing these compounds for individual patient prescriptions. It does not affect laboratory research use.
Does the FDA ban make BPC-157 and TB-500 illegal to buy?
No. The Category 2 503A action applies specifically to licensed compounding pharmacies under the 503A framework. It does not make possession of these compounds illegal for research purposes, and does not prohibit purchase of research-grade peptides from suppliers for laboratory use. Legal status for research chemicals is governed by separate frameworks.
What is the difference between 503A and 503B compounding?
503A facilities are traditional compounding pharmacies that prepare individualized prescriptions for specific patients. 503B facilities are FDA-registered outsourcing facilities that produce larger batches for healthcare facilities. The Category 2 action applies to 503A facilities. 503B facilities operate under different FDA oversight and may continue compounding some compounds under different regulatory conditions.
Are semaglutide and tirzepatide affected by the Category 2 action?
No. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved drugs and are governed by different regulatory frameworks. They require prescriptions for clinical use. The September 2024 action targeted unapproved research compounds, not FDA-approved pharmaceuticals.
When will retatrutide be FDA-approved?
No approval timeline has been officially announced. Phase 3 TRIUMPH trials are ongoing with results expected throughout 2026. The earliest realistic regulatory submission would be late 2026 or 2027, with potential approval in 2027-2028 if trials succeed. Retatrutide remains available only as a research peptide until approval.
What does 'research use only' mean legally?
Research-use-only (RUO) labeling indicates that a product is intended for laboratory and preclinical research applications and is not approved for human diagnostic, therapeutic, or clinical use. RUO products are sold to researchers and institutions for in vitro experiments, cell studies, and animal model research. They are not for human administration.
Related Research Guides
- Peptide Stacking
Complete Guide to Peptide Stacking
Evidence grades, FDA regulatory context, and protocol design for BPC-157, TB-500, CJC-1295 stacks.
- Weight Loss
Retatrutide: Phase 3 Weight Loss Data
-28.7% weight loss in Phase 3 — the investigational compound closest to FDA approval.
- Anti-Aging
GHK-Cu Anti-Aging Research Guide
4,000+ gene effects, topical vs injectable comparison, Wilson's disease contraindication.
- Education
How Peptides Work: Beginner's Guide
Foundational peptide science and the regulatory landscape for research peptides.